GeoVax Labs, Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
GeoVax Labs exchanged existing warrants to purchase 5,697,628 shares (exercise price $0.64) for gross proceeds of ~$3.6M with Armistice Capital Master Fund Ltd., an institutional investor. In return, GeoVax issued 11,395,256 new unregistered warrants (200% ratio) at $0.64/share, exercisable within 5 years of shareholder approval. Closing expected ~August 27, 2026. Net proceeds for working capital; shareholder vote required by October 29, 2026.
Why this rating
At ~$13.7M market cap, $3.6M gross cash (~26% of cap) is material; warrant dilution is steep but near-term positive for runway and reduces debt pressure versus $3.6M cash infusion.
Tradability signal
NO TRADE
No trade: only ~$30k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.72 ▲ 10.92% | at our read · backfill $0.65 | +10 min · backfill $0.60 ▼ 7.42% | +30 min · backfill $0.59 ▼ 9.40% | +1 hr · backfill $0.66 ▲ 1.78% |
The stock had already moved -9.85% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.